Guardant Health, Inc.

General information
Guardant Health, Inc.
3100 Hanover Street
94304 Palo Alto, California
USA

Contact person: Helmy Eltoukhy, Chairman and co-Chief Executive Officer
Company main phone: +1 (855) 6988887
Company main fax:  +1 (888) 9744258
Website:  https://www.guardanthealth.com
Year founded:2012
Source of foundation:Independent foundation
No. of employees: Worldwide:  1793
Corporate description / mission:
Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. The company's digital sequencing technology provides a picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2018
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Molecular diagnostics
  • Other
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Manufacturer
  • R&D
  • Service company
  • Supplier / Distributor
Customer segments:
  • Consumers (mass market)
  • Hospitals
  • Large medtech
  • Physicians / doctors
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Description of products:
Guardant360® CDx
Guardant Reveal™ test
LUNAR-2 test
Financing details
Fiscal year (end of) 2022
Revenues:USD 449.54M
R&D expenses:USD 373.81M
No. of shares:117'692'000
Market cap. / valuation:USD 4'120.40M
Collaborations & Clients
Partnering strategy / collaborations:
The company work with bio-pharmaceutical partners, digital health companies, patient advocacy groups and international distributors.
© 2023 Biotechgate by Venture Valuation
X